| Literature DB >> 31148893 |
Sulaiman I A Alsohaim1,2, Abdulkader A Bawadikji3, Ramadan Elkalmi4, Mohammed Imad Al-Deen M Mahmud5, Mohamed Azmi Hassali3.
Abstract
INTRODUCTION: Most of the decisions regarding diagnosis and treatment are based on laboratory test results. Urinary tract infections (UTIs) are among the most common infections in humans. The changing antimicrobial sensitivity in UTI requires appropriate antibiotics. Antimicrobial resistance is an emerging problem in the Kingdom of Saudi Arabia where the complete reversal of antimicrobial resistance is difficult due to irrational use of antibiotics.Entities:
Keywords: Antimicrobials; Saudi Arabia; bacterial isolates; resistance; urinary tract infections
Year: 2019 PMID: 31148893 PMCID: PMC6537636 DOI: 10.4103/jpbs.JPBS_217_18
Source DB: PubMed Journal: J Pharm Bioallied Sci ISSN: 0975-7406
Name and percentage of bacterial pathogens during different seasons
| Bacteria | August 2016 (%) | September 2016 (%) | October 2016 (%) | November 2016 (%) | December 2016 (%) | January 2017 (%) | |
|---|---|---|---|---|---|---|---|
| GNB (gram-negative bacilli) | Negative | 16.9 | 15.0 | 9.5 | 14.2 | 16.9 | 19.0 |
| Positive | 0.5 | 0.6 | 1.8 | 3.2 | 2.4 | 0.0 | |
| Negative | 17.4 | 15.6 | 11.3 | 17.2 | 18.2 | 15.6 | |
| Positive | 0.0 | 0.0 | 0.0 | 0.2 | 1.1 | 3.4 | |
| Negative | 15.8 | 14.8 | 10.6 | 16.9 | 18.7 | 19.0 | |
| Positive | 1.6 | 0.8 | 0.8 | 0.5 | 0.5 | 0.0 | |
| Negative | 17.2 | 15.0 | 11.1 | 17.2 | 17.7 | 17.9 | |
| Positive | 0.2 | 0.6 | 0.2 | 0.2 | 1.6 | 1.1 | |
| Negative | 16.1 | 15.0 | 11.3 | 17.4 | 18.7 | 17.9 | |
| Positive | 1.3 | 0.6 | 0.0 | 0.0 | 0.6 | 1.1 | |
| Negative | 17.4 | 15.6 | 11.3 | 16.9 | 17.9 | 17.4 | |
| Positive | 0.0 | 0.0 | 0.0 | 0.5 | 1.4 | 1.6 | |
| Negative | 16.6 | 15.0 | 11.3 | 17.2 | 19.0 | 18.2 | |
| Positive | 0.8 | 0.6 | 0.0 | 0.2 | 0.3 | 0.8 | |
| Negative | 17.2 | 15.0 | 10.8 | 17.4 | 18.7 | 19.0 | |
| Positive | 0.2 | 0.6 | 0.5 | 0.0 | 0.5 | 0.0 | |
| Negative | 16.6 | 15.3 | 11.1 | 17.4 | 18.7 | 19.0 | |
| Positive | 0.8 | 0.3 | 0.2 | 0.0 | 0.5 | 0.0 | |
| Negative | 17.4 | 15.6 | 11.1 | 17.4 | 19.0 | 19.0 | |
| Positive | 0.0 | 0.0 | 0.2 | 0.0 | 0.3 | 0.0 | |
| Negative | 17.4 | 15.6 | 11.1 | 17.4 | 19.0 | 19.0 | |
| Positive | 0.0 | 0.0 | 0.2 | 0.0 | 0.3 | 0.0 | |
| Coagulase-negative | Negative | 17.4 | 15.6 | 11.1 | 17.4 | 19.0 | 19.0 |
| Positive | 0.0 | 0.0 | 0.2 | 0.0 | 0.3 | 0.0 | |
Resistance and sensitivity pattern of significant most bacteria among antibiotics used (n = 44)
| Antibiotic | |||||||
|---|---|---|---|---|---|---|---|
| S (%) | R (%) | S (%) | R (%) | S (%) | R (%) | ||
| Gentamicin | Negative | 39 (40.6) | 47 (60.3) | 38 (39.6) | 46 (47.9) | ||
| Positive | 9 (9.4) | 2 (2.1) | 10 (10.4) | 2 (2.1) | |||
| Cefoxitin | Negative | 10 (13.2) | 54 (71.1) | ||||
| Positive | 7 (41.2) | 5 (8.5) | |||||
| Tienam | Negative | 29 (41.4) | 30 (42.9) | ||||
| Positive | 10 (14.3) | 1 (1.4) | |||||
| Cefuroxime | Negative | 9 (14.1) | 44 (68.8) | ||||
| Positive | 5 (7.8) | 6 (9.4) | |||||
| Cefotaxime | Negative | 8 (15.1) | 37 (69.8) | 10 (18.9) | 37 (69.8) | ||
| Positive | 6 (11.3) | 2 (3.8) | 4 (7.5) | 2 (3.8) | |||
| Ceftriaxone | Negative | 7 (14.6) | 37 (77.1) | 7 (14.6) | 36 (75.0) | ||
| Positive | 3 (6.3) | 1 (2.1) | 3 (6.3) | 2 (4.2) | |||
| Amikacin | Negative | 23 (46.0) | 15 (30.0) | 17 (21.8) | 47 (60.3) | ||
| Positive | 12 (24.0) | 0 (0.0) | 0 (0.0) | 14 (17.9) | |||
R = resistance, S = sensitivity
Resistance and sensitivity pattern of significant most bacteria among antibiotics used (n = 44)
| Antibiotic | Gram-negative bacilli | ||||
|---|---|---|---|---|---|
| S (%) | R (%) | S (%) | R (%) | ||
| Ceftazidime | Negative | 10 (22.2) | 18 (40.0) | ||
| Positive | 1 (2.2) | 16 (35.6) | |||
| Cefoxitin | Negative | 16 (21.1) | 37 (48.7) | ||
| Positive | 1 (1.3) | 22 (28.9) | |||
| Ampicillin | Negative | 16 (20.5) | 39 (50.0) | ||
| Positive | 1 (1.3) | 22 (28.2) | |||
| Cefotaxime | Negative | 12 (22.6) | 20 (37.7) | ||
| Positive | 2 (3.8) | 19 (35.8) | |||
| Trimethoprim/Sulfamethoxazole | Negative | 25 (40.3) | 33 (53.2) | ||
| Positive | 4 (6.5) | 0 (0.0) | |||
| Amikacin | Negative | 33 (66.0) | 11 (22.0) | ||
| Positive | 2 (4.0) | 4 (8.0) | |||
| Mupirocin | Negative | 22 (88.0) | 2 (8.0) | ||
| Positive | 0 (0.0) | 1 (4.0) | |||
| Fosfomycin | Negative | 49 (80.3) | 6 (9.8) | ||
| Positive | 3 (4.9) | 3 (4.9) | |||
R = resistance, S = sensitivity
Resistance and sensitivity pattern of significant most bacteria among antibiotics used (n = 44)
| Antibiotic | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| S (%) | R (%) | S (%) | R (%) | S (%) | R (%) | S (%) | R (%) | ||
| Ciprofloxacin | Negative | 38 (38.8) | 52 (53.1) | ||||||
| Positive | 0 (0.0) | 8 (8.2) | |||||||
| Teicoplanin | Negative | 39 (84.8) | 4 (8.7) | 39 (84.8) | 4 (8.7) | ||||
| Positive | 1 (2.2) | 2 (4.3) | 1 (2.2) | 2 (4.3) | |||||
| Trimethoprim/Sulfamethoxazole | Negative | 28 (45.2) | 25 (40.3) | ||||||
| Positive | 1 (1.6) | 8 (12.9) | |||||||
| Mupirocin | Negative | 22 (88.0) | 1 (4.0) | ||||||
| Positive | 0 (0.0) | 2 (8.0) | |||||||
| Tetracycline | Negative | 31 (42.9) | 27 (42.9) | ||||||
| Positive | 0 (0.0) | 5 (7.9) | |||||||
| Amikacin | Negative | 35 (70.0) | 9 (18.0) | 15 (19.2) | 61 (78.2) | ||||
| Positive | 0 (0.0) | 6 (12.0) | 2 (2.6) | 0 (0.0) | |||||
| Levofloxacin | Negative | 35 (46.1) | 36 (47.4) | ||||||
| Positive | 0 (0.0) | 5 (6.6) | |||||||
| Vancomycin | Negative | 22 (91.7) | 0 (0.0) | ||||||
| Positive | 1 (4.2) | 1 (4.2) | |||||||
R = resistance, S = sensitivity
Resistance and sensitivity pattern of significant most bacteria among antibiotics used (n = 44)
| Antibiotic | |||||||
|---|---|---|---|---|---|---|---|
| S (%) | R (%) | S (%) | R (%) | S (%) | R (%) | ||
| Ampicillin | Negative | 9 (11.5) | 58 (74.4) | ||||
| Positive | 8 (10.3) | 3 (3.8) | |||||
| Mupirocin | Negative | 22 (88.0) | 2 (8.0) | ||||
| Positive | 0 (0.0) | 1 (4.0) | |||||
| Cotrimox | Negative | 5 (14.3) | 29 (82.9) | ||||
| Positive | 1 (2.9) | 0 (0.0) | |||||
| Synercid | Negative | 24 (68.6) | 1 (2.9) | 14 (40.0) | 9 (25.7) | 19 (76.0) | 1 (4.0) |
| Positive | 2 (5.7) | 8 (22.9) | 12 (34.3) | 0 (0.0) | 3 (12.0) | 2 (8.0) | |
| Tetracycline | Negative | 30 (47.6) | 25 (39.7) | 19 (30.2) | 29 (46.0) | ||
| Positive | 1 (1.6) | 7 (11.1) | 12 (19.0) | 3 (4.8) | |||
| Amikacin | Negative | 35 (70.0) | 13 (26.0) | ||||
| Positive | 0 (0.0) | 2 (4.0) | |||||
| Levofloxacin | Negative | 33 (43.4) | 30 (39.5) | ||||
| Positive | 2 (2.6) | 11 (14.5) | |||||
| Tienam | Negative | 39 (55.7) | 27 (38.6) | ||||
| Positive | 0 (0.0) | 4 (5.7) | |||||
R = resistance, S = sensitivity